Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Philip Grant, MD
Stanford University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama Birmingham
Birmingham, Alabama, United States
- Stanford University
Palo Alto, California, United States
- University of Colorado
Aurora, Colorado, United States
- Emory
Atlanta, Georgia, United States
- Northwestern
Chicago, Illinois, United States
- Johns Hopkins
Baltimore, Maryland, United States
- Columbia
New York, New York, United States
- Penn
Philadelphia, Pennsylvania, United States
- Dallas Va Medical Center
Dallas, Texas, United States
- Ut Houston
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Aug 2019
- Primary completion
- 1 Jul 2021
- Completion
- 1 Jul 2021
- Last update posted
- 15 Mar 2021
- Registered enrollment
- 0
- Registry id
- NCT03549689
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.